Scientists probe hidden drug battle inside diabetic bodies
NCT ID NCT07053319
Summary
This early-stage study aims to understand how two common type 2 diabetes medications, empagliflozin and pioglitazone, interact in the body. Researchers will measure how they affect the body's production of sugar, fat breakdown, and ketones in 64 participants. The goal is to gather detailed knowledge about these drug interactions to inform future treatment approaches.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Diabetes Institute/UH
RECRUITINGSan Antonio, Texas, 78229-3900, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.